Peptide Therapeutics Market Size (2024 - 2029)

Peptide Therapeutics Market Analysis

The Peptide Therapeutics Market size is estimated at USD 43.30 billion in 2024, and is expected to reach USD 60.90 billion by 2029, growing at a CAGR of 7.06% during the forecast period (2024-2029).

The COVID-19 pandemic substantially impacted the peptide therapeutics market. The pandemic surged the need for the development of novel peptides. In April 2022, an article published in the IJPRT journal reported the companies had developed peptide-based vaccines for COVID-19 treatment. Thus, initially, the growth of the peptide therapeutics market was driven by the increase in COVID-19 cases, as peptide therapeutics were reported efficacious for the treatment of Sars-CoV-2 infection. However, in the current scenario, as the pandemic has declined, the market may get negatively impacted. However, it is anticipated that with the efficacy of peptide therapeutics in treating other chronic diseases, the studied market will witness stable growth over the forecast period.

The major factors driving the market growth are the increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements in peptide therapeutics.

Cancer cases are increasing worldwide. Globocan 2020 reported that by 2040, cancer cases worldwide are expected to increase by 56.7% of the current cancer cases. Studies have reported the significant results of peptide therapeutics in cancer treatment. For instance, in February 2021, an article published in the journal SCB reported that new-generation peptide therapeutics target cancer-specific signatures. Hence, they hold enormous potential for cancer therapy and diagnosis. Therefore, the increasing number of cancer cases and the significant effect of peptide therapeutics in cancer treatment is driving the growth of the studied market.

Also, the rising prevalence of some metabolic disorders, such as genetic disorders, organ dysfunction, and mitochondrial dysfunction, is fueling the growth of the studied market. Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder characterized by progressive glucocerebroside storage in macrophages, predominantly in bone, bone marrow, liver, and spleen. In July 2022, an article published in the journal JPHO asserted that the prevalence of GD in global birth was 1.5 cases per 100,000 live births. The overall global prevalence of GD was 0.9 cases per 100,000 inhabitants. The high prevalence of such metabolic disorders is fueling the demand for peptide therapeutics for treating metabolic disorders, thereby driving the growth of the studied market.

Furthermore, the technological development and introduction of new peptide therapeutics for treating chronic diseases like cancer are also fueling the growth of the studied market. In May 2021, ISSAR Pharmaceuticals decided to license out its peptide-based new NCEs with pre-IND filing and the United States patent for various unmet healthcare needs of the population, making it affordable and accessible for better health outcomes. Such developments are driving the growth of the studied market.

Therefore, the studied market is expected to witness significant growth over the forecast period due to the increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements. However, instability issues of peptide therapeutics, the high cost of developing drugs, and stringent regulatory requirements for drug approval are expected to restrain the market growth.

Peptide Therapeutics Industry Segmentation

Peptides are short chains of amino acid monomers linked by peptide bonds. Peptides are distinguished from proteins based on size and, as a benchmark, can be understood to contain approximately 50 amino acids or less. 

The Peptide Therapeutics Market is Segmented by Marketing Type (Generic and Branded), Application (Gastrointestinal Disorders, Neurological Disorders, Metabolic Disorders, Cancer, and Other Applications), Route of Administration (Parenteral, Oral, and Other Routes of Administration), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD million) for all the above segments.